Dynavax Technologies Corporation (DVAX)
NASDAQ: DVAX · Real-Time Price · USD
12.72
-0.04 (-0.31%)
Dec 20, 2024, 4:00 PM EST - Market closed
Dynavax Technologies Revenue
Dynavax Technologies had revenue of $80.63M in the quarter ending September 30, 2024, with 15.99% growth. This brings the company's revenue in the last twelve months to $260.81M, down -27.79% year-over-year. In the year 2023, Dynavax Technologies had annual revenue of $232.28M, down -67.86%.
Revenue (ttm)
$260.81M
Revenue Growth
-27.79%
P/S Ratio
6.36
Revenue / Employee
$639,240
Employees
408
Market Cap
1.67B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 232.28M | -490.40M | -67.86% |
Dec 31, 2022 | 722.68M | 283.24M | 64.45% |
Dec 31, 2021 | 439.44M | 399.19M | 991.75% |
Dec 31, 2020 | 40.25M | 5.03M | 14.29% |
Dec 31, 2019 | 35.22M | 27.02M | 329.60% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fortrea Holdings | 2.98B |
Clover Health Investments | 2.12B |
Integra LifeSciences Holdings | 1.56B |
10x Genomics | 629.74M |
Certara | 372.80M |
Arcutis Biotherapeutics | 138.71M |
Xencor | 85.16M |
Celldex Therapeutics | 9.98M |
DVAX News
- 25 days ago - Dynavax to Present at the 7th Annual Evercore HealthCONx Conference - PRNewsWire
- 5 weeks ago - Dynavax Technologies: What The Stock Buyback Means. What It Doesn't - Seeking Alpha
- 5 weeks ago - Dynavax Announces $100 Million Accelerated Share Repurchase Program - PRNewsWire
- 6 weeks ago - Dynavax Technologies Corporation (DVAX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates - PRNewsWire
- 6 weeks ago - Dynavax Announces $200 Million Share Repurchase Program - PRNewsWire
- 6 weeks ago - Glancy Prongay & Murray LLP Announces Investigation of Dynavax Technologies Corporation (DVAX) - Business Wire
- 7 weeks ago - Dynavax Adopts Limited-Duration Stockholder Rights Plan - PRNewsWire